New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
Recruiting
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/27/2024
Locations: University of Buffalo, Buffalo, New York
Conditions: Ischemic Stroke, Neovascularization
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Recruiting
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/27/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: MDS, AML, ALL, MPD Withou Myelofibrosis, NHL or HL, Inherited Metabolic Disorders, Hemoglobinopathies, Bone Marrow Failure, HLH
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIOâ„¢ (Pexidartinib) Treatment
Recruiting
A study to evaluate the long-term risk of hepatic failure with TURALIOâ„¢ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIOâ„¢ (pexidartinib) and experience hepatotoxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Montefiore Medical Center, New York, New York
Conditions: Hepatotoxicity, Tenosynovial Giant Cell Tumor
Cardiac Sarcoidosis Randomized Trial
Recruiting
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than sta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Montefiore Medical Center, New York, New York
Conditions: Cardiac Sarcoidosis, Sarcoidosis
Examining Executive Functions in Medical Students Across Different Types of Study Breaks
Recruiting
This study aims to expand on previous findings and compare the effects of an active break (ten minutes of walking or upper body movement), a digital break (ten minutes of phone use), and no break on memory and attention in medical students after a prolonged period of studying. The List Learning Task, Stroop Test, and Sustained Attention to Response Task will be administered to measure memory, executive function, and attention, respectively. Information on how different types of breaks affect mem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: NYIT, Old Westbury, New York
Conditions: Executive Function (Cognition)
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
Recruiting
The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy. There are no risks for the patients, as this is a retrospective data collection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Non-Small Cell Lung Cancer
Community Health Worker Assisted Task Specific and Cognitive Therapy At Home with Exposure After Stroke
Recruiting
CATCHES is a novel intervention for preliminary testing, integrating Task Specific Therapy at home guided by Community Health Workers (CHW) under supervision of a licensed Physical Therapist (PT) guided by telehealth based Cognitive Behavioral Therapy (CBT) to reduce task specific fears through repetitive exposure and adaptive behavioral activation strategies and facilitate engagement in physical activity. 1. To integrate and establish feasibility of CATCHES intervention. Hypothesis: A multidis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: The Neurological Institute of New York, Columbia University, New York, New York
Conditions: Stroke, Acute Ischemic
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Recruiting
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
Conditions: GIST
Daratumumab in Primary Antiphospholipid Syndrome
Recruiting
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab acc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/26/2024
Locations: Northwell Health, Great Neck, New York
Conditions: Autoimmune Disorders
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Ichan School of Medicine at Mount Sinai, New York, New York
Conditions: Advanced Cancer
Dorsal Root Ganglion Stimulation for the Treatment of Arthritic Knee Pain
Recruiting
Dorsal root ganglion stimulation (DRG-S) may be able to treat mechanical pain caused by tissue injury or damage such as trauma or arthritis in addition to pain caused by nerve dysfunction or injury. The purpose of this study is to determine if dorsal root ganglion stimulation (DRG-S) can effectively treat arthritic pain of the knee.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/26/2024
Locations: The Spine and Pain Institute of New York, New York, New York
Conditions: Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis, Knee Arthropathy
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Recruiting
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Weill Cornell Medical College, New York, New York
Conditions: Metastatic Prostate Cancer